Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Group 1 - Sutro Biopharma, Inc. is a clinical-stage oncology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) [1][2] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET [1] - Sutro's technology, including cell-free XpressCF, aims to enhance patient benefits and experiences through precisely designed cancer therapeutics [2] Group 2 - Sutro has multiple clinical-stage candidates, including luveltamab tazevibulin (luvelta), which is a registrational-stage ADC targeting folate receptor alpha (FolRα) [2] - The company has established high-value collaborations and industry partnerships that support its continuous product innovation [2] - Sutro is headquartered in South San Francisco and provides additional information through its website and social media [2]